ABC Maintenance Therapy for Newly Diagnosed Acute Myeloid Leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a maintenance treatment (ABC therapy) for patients with acute myeloid leukemia (AML, a blood cancer) who have responded well to initial chemotherapy. The goal is to help keep the cancer in remission longer and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–80 years old with newly diagnosed AML
- You must have achieved complete remission (cancer in full response) after intensive chemotherapy plus at least 2 cycles of consolidation therapy, within the last 4 months
- Your overall health status (ECOG score) must be 0–3, meaning you can still do most daily activities
- Your liver, kidney, and blood cell counts must meet specific thresholds (your doctor will check these)
- You cannot have active infections, uncontrolled heart problems, or uncontrolled psychiatric conditions
- If you are a woman who can become pregnant, you must agree to pregnancy testing and use two forms of birth control during and for 28 days after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial tests whether a maintenance treatment with a hypomethylating agent can help keep favorable-risk acute myeloid leukemia (AML) patients in remission after they have completed initial therapy. It is designed for patients who have achieved negative minimal residual disease (MRD) and have not received a stem cell transplant.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
This Phase 2 trial tests a combination treatment to try to get rid of remaining cancer cells in young adults whose acute myeloid leukemia (AML) is in remission but still detectable at low levels. It may help patients eliminate “minimal residual disease” (small traces of leukemia cells) and reduce relapse risk.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
Hear when a new Acute Myeloid Leukemia (AML) in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.